Justin Mansfield, MD
Internal Medicine · Ogden, UTNPI 1699707059
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 1,077 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,553 and has fallen 51.0% since, to $1,742 in 2025. Among internal medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,077 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$1K
- Astellas Pharma US Inc$675
- Novartis$667
- plus $7K from 54 others
Across 132 payments — averaging $23,531 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$2.1M
- Eli Lilly$663K
- Janssen Research & Development, LLC$132K
- Pfizer$126K
- Tolmar, Inc.$36K
- Alnylam Pharmaceuticals Inc.$14K
- plus $34K from 5 others
What the payments were for
- Consulting fees$1,2007%
- Food & beverage$15,05392%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- EVENITY$116
How this compares
$16,360 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $92,381 |
| XareltoRivaroxaban | 69 | $84,930 |
| EliquisApixaban | 83 | $74,285 |
| MyrbetriqMirabegron | 64 | $55,031 |
| LinzessLinaclotide | 37 | $33,497 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $32,548 |
| MounjaroTirzepatide | 28 | $30,810 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $25,955 |
| JanuviaSitagliptin Phosphate | 27 | $23,926 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $17,400 |
| Levemir FlexpenInsulin Detemir | 26 | $14,676 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 350 | $11,567 |
| FarxigaDapagliflozin Propanediol | 14 | $11,471 |
| GemtesaVibegron | 16 | $10,759 |
| Repatha SureclickEvolocumab | 20 | $10,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,421 | $92,38148 claims |
| Johnson & JohnsonXarelto | $199 | $84,93069 claims |
| PfizerEliquis | $613 | $74,28583 claims |
| Astellas Pharma US IncMyrbetriq | $675 | $55,03164 claims |
| AbbVieLinzess, Synthroid | $3,761 | $36,37572 claims |
| Lilly USA, LLCMounjaro | $614 | $30,81028 claims |
| MerckJanuvia | $63 | $23,92627 claims |
| AstraZenecaFarxiga | $263 | $11,47114 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $168 | $10,75916 claims |
| GSKBreo Ellipta | $383 | $5,38213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Ogden
- Celine RiveraOgden$11K
- Matthew ReddOgden$8K
- Scott MoultonOgden$7K
- Donna MilavetzOgden$7K
- Robert MohrOgden$7K
- Kendell CoburnOgden$4K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.